LabAutomation 2006 - SLAS

Where Laboratory Technologies Emerge and Merge
3:30 pm Tuesday, January 24, 2006 Track 1: Detection & Separation Room: Catalina
Wyndham Palm Springs Hotel
James Rubenstein
Co-Author(s)
University of California, San Francisco
Mimi Roy, Chris Becker, Howard Schulman
San Francisco, California
jamesr@medicine.ucsf.edu
PPD
Toward Lymphoma Biomarkers: Deep-Look Mass Spectrometry-Based Expression
Profiling, Identification and Validation in the Cerebrospinal Fluid.
Central nervous system lymphoma is usually an aggressive form of non-Hodgkin’s lymphoma. The current means for establishing its
diagnosis are 1) brain biopsy, which is associated with risk of brain hemorrhage; or 2) cytological analysis of the cerebrospinal fluid (CSF),
which is insensitive in over 50% of cases. The identification of sensitive and specific biomarkers are needed to facilitate early, non-invasive
diagnosis of this disease. We are testing the hypothesis that such biomarkers are present in the CSF.
We describe a two-dimensional liquid chromatography-mass spectrometry-based method for differential quantification and identification
of several hundred CSF proteins. Proprietary spectral interpretation and intensity-normalization software were developed to quantify the
difference in expression level of proteins between controls and lymphoma patients in CSF using relative component intensities. No isotope
tags were used.
An application of this approach to biomarker discovery in CSF is presented. We performed two sets of analyses using independent CSF
specimens. In the experimental set we compared the pattern of expression in 9 control vs 9 cases of CNS lymphoma. 130 peptides
were differentially expressed between the two groups (p